SCHEMBL4534870

SCHEMBL4534870

Cc1cccc(-c2cccc(-c3cnc(N)o3)c2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 2/20 0.47
FLT1 P17948 1/20 0.47
FLT4 P35916 1/20 0.47
RAB9A P51151 3/20 0.45
HPGD P15428 3/20 0.45
ALDH1A1 P00352 3/20 0.45
NPC1 O15118 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
TP53 P04637 2/20 0.45
HSD17B10 Q99714 2/20 0.45
POLB P06746 1/20 0.45
MAP4K4 O95819 2/20 0.43
TSHR P16473 1/20 0.42
ADORA1 P30542 1/20 0.42
ATR Q13535 1/20 0.42
SLC9A1 P19634 2/20 0.42
IDO1 P14902 1/20 0.41
METAP2 P50579 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4530786 0.92 RAB9A (0.41) KDRFLT1FLT4RAB9AHPGD
SCHEMBL4528767 0.85 RAB9A (0.47) KDRFLT1FLT4RAB9AHPGD
SCHEMBL4539660 0.81 HSD17B1 (0.55) HPGDALDH1A1MAP4K4ADORA1METAP2
SCHEMBL4532640 0.80 RXRA (0.40) KDRFLT1FLT4RAB9AALDH1A1
SCHEMBL4527592 0.80 KIT (0.45) RAB9AHPGDALDH1A1NPC1SMN1; SMN2
SCHEMBL12266930 0.80 FLT1 (0.51) KDRFLT1FLT4RAB9AHPGD
SCHEMBL14650182 0.80 MAP4K4 (0.54) RAB9AALDH1A1NPC1MAP4K4METAP2
SCHEMBL16785553 0.79 FLT1 (0.46) KDRFLT1FLT4RAB9AHPGD
SCHEMBL4534098 0.79 RAB9A (0.44) RAB9AHPGDALDH1A1NPC1MAP4K4
SCHEMBL4537136 0.79 MEN1 (0.56) KDRFLT1FLT4RAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090018150-A1 5-Ht2b Receptor Antagonists ASTERAND UK LIMITED (GB) 2009-01-15 US disclosed
US-20090018150-A1 5-Ht2b Receptor Antagonists ASTERAND UK LIMITED (GB) 2009-01-15 US disclosed
US-20090018150-A1 5-Ht2b Receptor Antagonists ASTERAND UK LIMITED (GB) 2009-01-15 US disclosed
EP-1648876-A1 5-HT SB 2B /SB RECEPTOR ANTAGONISTS Pharmagene Laboratories Ltd (GB) 2006-04-26 EP disclosed
WO-2005012263-A1 5-HT2B RECEPTOR ANTAGONISTS PHARMAGENE LABORATORIES LIMITED (GB) 2005-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018150-A1 5-Ht2b Receptor Antagonists HTR2B, HTR1B, HTR3B KDR 803/4885FLT1 1508/4885FLT4 1271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.